DCF — ST. CHARLES MED CTR-REDMOND
Enterprise Value: $108.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$108.7M
Enterprise Value
$29.5M
PV of Cash Flows
$79.2M
PV of Terminal Value
$127.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $102.2M | $13.2M | 13.0% | $6.2M | $5.6M |
| Year 2 | $105.2M | $14.6M | 14.0% | $7.2M | $5.9M |
| Year 3 | $108.4M | $16.1M | 15.0% | $8.2M | $6.2M |
| Year 4 | $111.7M | $17.2M | 15.0% | $8.9M | $6.0M |
| Year 5 | $115.0M | $18.0M | 16.0% | $9.3M | $5.8M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $108.7M. Terminal value accounts for 73% of total EV — typical range (60-80%).
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$99.2M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.12379434205086641
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5